Inhibikase Therapeutics: director resignation and appointment

What happened The filing reported that Dennis Berman resigned from the board of directors and his roles as chair of the compensation committee and as a member of the audit committee, effective Oct 19, 2026. The filing reported that, on Oct 19, 2026, the board appointed Scott Wasserman to serve as a Class III director, effective Oct 19, 2026, and that Dr. Wasserman will serve as a member of the compensation committee and was determined to be independent under Nasdaq and SEC rules. The filing said Mr. Berman advised the Company that his decision to resign "was not the result of any disagreement with the Company or its management on any matter relating to the Company’s operations, policies or practices."

Key details

• Dennis Berman resigned effective Oct 19, 2026.
• Scott Wasserman was appointed effective Oct 19, 2026, as a Class III director to hold office until the annual meeting of stockholders in 2029.
• Dr. Wasserman will receive an initial new director grant of non-qualified stock options to purchase up to 310,000 shares and cash compensation under the Company’s Non-Employee Director Compensation Policy.
• The company issued a press release titled "Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors" on Oct 20, 2026 (Regulation FD disclosure).

Why it may matter This 8-K reports items under Item 5.02 (departure of directors or certain officers; election of directors) and Item 7.01 (Regulation FD disclosure). The filing describes the resignation, the board appointment, committee assignment, compensation arrangements for the new director, and the press release. The filing does not show why the insider traded or why the company acted.